Leo Howell of Georgia Tech — The Nexus of Cybersecurity, Automation, and Artificial Intelligence
March 19, 2024
Leave a comment
Tag
Gregory S. Smith is the CIO of the American Kidney Fund, a professor at Georgetown University, and the author of five books, the most recent of which is The New Normal in IT: How the Global Pandemic Changed Information Technology Forever. In this interview we talk about his new book and his thoughts on the pandemic and post-pandemic business landscape. Did COVID-19 accelerate trends that were already in the process of becoming the new normal, or was a worldwide disruption of this magnitude necessary to transform our working lives? How has technology allowed us to weather this crisis, and what have we learned from the experience that will inform our future business decisions? Is hybrid and remote work here to stay? How does that inform the ongoing conversations about attracting and retaining top talent?
We also speak about Executive Platforms’ upcoming new series, the North American Technology Executive Summit, and some of the big ideas and key themes that will be included in its agenda. What should CIOs and CTOs be working on right now to position their organizations best for a future whose ‘New Normal’ is still being defined?
Continue reading
At the most recent edition of the Pharma Manufacturing World Summit held May 15-16, 2023, in Boston, we spoke with Michael Kamarck, a senior industry executive, and Pascal Bécotte, the Managing Director of Russell Reynolds Associates, about the most serious challenge threatening to bottleneck the otherwise very bright future of medicine. For a number of reasons explored in both this interview and in this recent blog post, there are not enough qualified people to fill all the top jobs that need to be done, and this is not something that is going to be fixed in a day or even a few years without the industry working together in a decisive and unprecedented way to collectively develop its rising Top Talent in the technical operations space into the senior leaders that Small Molecule, Large Molecule, and especially the emerging Advanced Therapy Medicinal Products sectors cannot do without.
Continue reading
